NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Corporate Updates: NewAmsterdam Pharma reported a strong financial position with $808.5 million in cash as of March 31, 2025, and is progressing with its clinical trials for obicetrapib, an oral LDL-C lowering therapy, with significant data expected from ongoing Phase 3 trials.
Regulatory and Clinical Developments: The company anticipates submitting an application to the EMA in the second half of 2025 and plans to present additional trial data at upcoming medical conferences, highlighting obicetrapib's potential in managing cardiovascular disease.
Trade with 70% Backtested Accuracy
Analyst Views on NAMSW
No data
About the author
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule: The report highlights the specific NASDAQ listing rule 5635(c)(4) related to these inducement grants.
Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144
Company Announcement: New Amsterdam Pharma intends to sell 200,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Obicetrapib's Impact on Alzheimer's Biomarkers: The clinical trial results indicate that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, particularly in ApoE4 carriers, suggesting its potential as a preventive treatment for Alzheimer's.
Dual Benefits of Obicetrapib: In addition to lowering LDL cholesterol levels, obicetrapib shows promise in addressing both neurodegenerative and cardiovascular risks, highlighting its unique therapeutic profile in treating patients at risk for these conditions.
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
Alzheimer's Disease Biomarker Findings: NewAmsterdam Pharma announced that their treatment, obicetrapib, showed significant reductions in Alzheimer's disease biomarkers in a Phase 3 trial, particularly among ApoE4 carriers, indicating potential for AD prevention alongside cardiovascular benefits.
Upcoming Presentation: The full results of the Alzheimer's sub-study will be presented at the Alzheimer's Association International Conference in Toronto in July 2025, highlighting the implications of CETP inhibition in mitigating Alzheimer's disease risk.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
Upcoming Investor Conferences: NewAmsterdam Pharma will participate in several investor conferences, including the William Blair Annual Growth Stock Conference on June 3, Jefferies Global Healthcare Conference on June 4, and Goldman Sachs Annual Healthcare Conference on June 9, 2025, with presentations from key executives.
Company Overview: NewAmsterdam Pharma is focused on developing oral, non-statin therapies for patients at risk of cardiovascular disease due to elevated LDL cholesterol, aiming to provide effective and well-tolerated treatment options through their investigational drug obicetrapib.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule: The report highlights the specific NASDAQ listing rule 5635(c)(4) related to these inducement grants.
Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144
Company Announcement: New Amsterdam Pharma intends to sell 200,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Obicetrapib's Impact on Alzheimer's Biomarkers: The clinical trial results indicate that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, particularly in ApoE4 carriers, suggesting its potential as a preventive treatment for Alzheimer's.
Dual Benefits of Obicetrapib: In addition to lowering LDL cholesterol levels, obicetrapib shows promise in addressing both neurodegenerative and cardiovascular risks, highlighting its unique therapeutic profile in treating patients at risk for these conditions.
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
Alzheimer's Disease Biomarker Findings: NewAmsterdam Pharma announced that their treatment, obicetrapib, showed significant reductions in Alzheimer's disease biomarkers in a Phase 3 trial, particularly among ApoE4 carriers, indicating potential for AD prevention alongside cardiovascular benefits.
Upcoming Presentation: The full results of the Alzheimer's sub-study will be presented at the Alzheimer's Association International Conference in Toronto in July 2025, highlighting the implications of CETP inhibition in mitigating Alzheimer's disease risk.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
Upcoming Investor Conferences: NewAmsterdam Pharma will participate in several investor conferences, including the William Blair Annual Growth Stock Conference on June 3, Jefferies Global Healthcare Conference on June 4, and Goldman Sachs Annual Healthcare Conference on June 9, 2025, with presentations from key executives.
Company Overview: NewAmsterdam Pharma is focused on developing oral, non-statin therapies for patients at risk of cardiovascular disease due to elevated LDL cholesterol, aiming to provide effective and well-tolerated treatment options through their investigational drug obicetrapib.
